1/16
01:51 pm
gmab
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Yahoo! Finance]
Low
Report
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Yahoo! Finance]
1/16
01:31 pm
gmab
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Medium
Report
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
1/16
01:30 pm
gmab
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Medium
Report
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
1/16
12:32 am
gmab
Is Genmab (CPSE:GMAB) Pricing Reflect Its Recent Biotech Momentum And DCF Upside Potential [Yahoo! Finance]
Medium
Report
Is Genmab (CPSE:GMAB) Pricing Reflect Its Recent Biotech Momentum And DCF Upside Potential [Yahoo! Finance]
1/15
02:36 pm
gmab
Genmab A/S (GMAB): A Bull Case Theory [Yahoo! Finance]
Low
Report
Genmab A/S (GMAB): A Bull Case Theory [Yahoo! Finance]
1/11
05:01 pm
gmab
Anthropic unveils Claude for Healthcare, expands life science features, and partners with HealthEx to let users connect medical records [Fortune]
Low
Report
Anthropic unveils Claude for Healthcare, expands life science features, and partners with HealthEx to let users connect medical records [Fortune]
1/10
05:26 am
gmab
Genmab: AI Partnership And Clinical Data Fuel Growth [Seeking Alpha]
Low
Report
Genmab: AI Partnership And Clinical Data Fuel Growth [Seeking Alpha]
1/7
09:18 am
gmab
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence [Yahoo! Finance]
Low
Report
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence [Yahoo! Finance]
1/7
09:00 am
gmab
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
Low
Report
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
1/5
03:24 am
gmab
Assessing Genmab (CPSE:GMAB) Valuation As Share Price Momentum Shows Signs Of Cooling [Yahoo! Finance]
Low
Report
Assessing Genmab (CPSE:GMAB) Valuation As Share Price Momentum Shows Signs Of Cooling [Yahoo! Finance]
12/31
08:48 am
gmab
Here's Why Genmab A/S (GMAB) Rose in Q3 [Yahoo! Finance]
Low
Report
Here's Why Genmab A/S (GMAB) Rose in Q3 [Yahoo! Finance]
12/30
09:12 am
gmab
Genmab shelves Phase III lung cancer candidate [Yahoo! Finance]
Low
Report
Genmab shelves Phase III lung cancer candidate [Yahoo! Finance]
12/29
09:16 am
gmab
Genmab scraps development of experimental cancer therapy [Yahoo! Finance]
Low
Report
Genmab scraps development of experimental cancer therapy [Yahoo! Finance]
12/29
08:23 am
gmab
Genmab Portfolio Prioritization Update [Yahoo! Finance]
Low
Report
Genmab Portfolio Prioritization Update [Yahoo! Finance]
12/29
08:12 am
gmab
Genmab Portfolio Prioritization Update
Low
Report
Genmab Portfolio Prioritization Update
12/29
08:10 am
gmab
Genmab Portfolio Prioritization Update
Low
Report
Genmab Portfolio Prioritization Update
12/15
02:30 am
gmab
Does Genmab's 2025 Rally Match Its DCF and Earnings Valuation Outlook? [Yahoo! Finance]
Low
Report
Does Genmab's 2025 Rally Match Its DCF and Earnings Valuation Outlook? [Yahoo! Finance]
12/12
02:14 am
gmab
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period [Yahoo! Finance]
Medium
Report
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period [Yahoo! Finance]
12/12
01:52 am
gmab
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period [Yahoo! Finance]
Medium
Report
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period [Yahoo! Finance]
12/12
01:36 am
gmab
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Medium
Report
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
12/12
01:35 am
gmab
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Medium
Report
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
12/11
04:24 pm
gmab
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript [Seeking Alpha]
Medium
Report
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript [Seeking Alpha]
12/11
03:18 am
gmab
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting [Yahoo! Finance]
Medium
Report
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting [Yahoo! Finance]
12/10
12:52 pm
gmab
ASH 2025: AbbVie and Genmab's Epkinly sets new standard in second-line FL [Yahoo! Finance]
Low
Report
ASH 2025: AbbVie and Genmab's Epkinly sets new standard in second-line FL [Yahoo! Finance]
12/8
04:30 pm
gmab
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Medium
Report
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)